| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/29/2001 | WO2000063386A3 Prevention, diagnosis and treatment of lyme disease |
| 03/29/2001 | WO2000061067A3 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein |
| 03/29/2001 | US20010000075 Neurotactin and uses therefor |
| 03/29/2001 | DE19944122A1 Treatment of inflammatory diseases in mammals comprises administration of complex formed from immunoglobulin and histamine |
| 03/29/2001 | DE19938767A1 Producing cleavage vaccines, especially influenza vaccines, of high immunogenicity, comprises cleaving a lipid capsule of virus particles using a fatty acid or its salt |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2793128A1 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors |
| 03/29/2001 | CA2404709A1 Highly efficient dendritic cell-targeted dna-vaccination |
| 03/29/2001 | CA2386767A1 Novel human protease inhibitor-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385879A1 Traf4 associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385813A1 Human endothelin converting enzyme-like proteins and polynucleotides encoding the same |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2385428A1 Novel pcna-associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385425A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2385404A1 Use of an outer membrane protein a of an enterobacterium associated with a rsv immunogenic peptide for preparing vaccines for intranasal administration |
| 03/29/2001 | CA2384812A1 Method and compositions for inhibiting adhesion formation |
| 03/29/2001 | CA2384806A1 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
| 03/29/2001 | CA2383629A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | CA2383615A1 Methods for diagnosis and therapy of hematological and virus-associated malignancies |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2383462A1 Therapeutic methods and compounds |
| 03/29/2001 | CA2383433A1 Oral recombinant lactobacilli vaccines |
| 03/29/2001 | CA2383413A1 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | CA2383110A1 Adjuvant comprising a polyoxyethylene alkyl ether or ester and at least one non-ionic surfactant |
| 03/29/2001 | CA2377525A1 Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| 03/29/2001 | CA2319213A1 Nucleic acids and proteins of the mycoplasma hyopneumoniae mhp3 gene and uses thereof |
| 03/28/2001 | EP1087014A1 Hog cholera virus vaccine and diagnostic |
| 03/28/2001 | EP1087013A2 Immunoglobulins devoid of light chains |
| 03/28/2001 | EP1086705A1 Vegf activity inhibitors |
| 03/28/2001 | EP1086252A1 Herpes simplex virus origin binding protein n-terminal truncation (obp-nt) |
| 03/28/2001 | EP1086239A1 Formulations for electroporation |
| 03/28/2001 | EP1086232A1 A vaccine-induced hepatitis b viral strain and uses thereof |
| 03/28/2001 | EP1086231A2 ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220 |
| 03/28/2001 | EP1086229A2 Moraxella catarrhalis polynucleotides and polypeptides |
| 03/28/2001 | EP1086228A1 Recombinant production of toxoplasma sag1 antigen |
| 03/28/2001 | EP1086225A2 Human tumour-derived polypeptide hormone phosphatonin |
| 03/28/2001 | EP1086224A1 B2 microglobulin fusion proteins and high affinity variants |
| 03/28/2001 | EP1086223A2 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 03/28/2001 | EP1086219A2 Proteins regulating gene expression |
| 03/28/2001 | EP1086215A2 Preparation and use of superior vaccines |
| 03/28/2001 | EP1086207A1 Novel methods and interferon deficient substrates for the propagation of viruses |
| 03/28/2001 | EP1086138A2 Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| 03/28/2001 | EP1086137A1 Composition and method for modulating dendritic cell-t cell interaction |
| 03/28/2001 | EP1086136A1 Monoclonal antibodies specific for guanidino group-derived advanced glycosylation endproducts in biological samples |
| 03/28/2001 | EP1086127A1 Novel compounds |
| 03/28/2001 | EP1086125A1 Respiratory nitrate reductase alpha subunit |
| 03/28/2001 | EP1086066A1 Muscarinic receptor antagonists |
| 03/28/2001 | EP1085906A1 Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease |
| 03/28/2001 | EP1085905A1 Immunotherapeutic composition and method for the treatment of prostate cancer |
| 03/28/2001 | EP1085904A1 Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals |
| 03/28/2001 | EP1085903A1 Egg surface proteins and methods for use for modulating fertility |
| 03/28/2001 | EP1085902A2 Therapeutic compositions that produce an immune response by altering the antigen |
| 03/28/2001 | EP1085898A1 Parasite antigens |
| 03/28/2001 | EP1085897A1 Acrp30r1l, a homolog of acrp30 (30 kd adipocyte complement-related protein) |
| 03/28/2001 | EP1085895A1 Bradykinin antagonists |
| 03/28/2001 | EP1085893A1 Phosphodiesterase-v modulator drugs and their uses |
| 03/28/2001 | EP1085892A2 Vaccination strategy to prevent and treat cancers |
| 03/28/2001 | EP1085891A1 Multibinding inhibitors of topoisomerase |
| 03/28/2001 | EP1085888A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht 3? receptors |
| 03/28/2001 | EP1085882A2 Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| 03/28/2001 | EP1085863A1 Cross-reference to related applications |
| 03/28/2001 | EP1085861A1 Inhibitors of nitric oxide synthase |
| 03/28/2001 | EP1085857A2 Cationic amphiphile micellar complexes |
| 03/28/2001 | EP1085846A2 Multibinding inhibitors of microsomal triglyceride transferase protein |
| 03/28/2001 | EP1085842A2 Apparatus and methods for preparing an implantable graft |
| 03/28/2001 | EP0831897B1 In ovo vaccination against coccidiosis |
| 03/28/2001 | EP0759087B1 Compositions and methods for targeting gene delivery vehicles |
| 03/28/2001 | CN1289339A Genetic immunization with nonstructural proteins of hepatitis c virus |
| 03/28/2001 | CN1289253A Treating atopic dermatitis with lgE antagonists |
| 03/28/2001 | CN1289252A Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway |
| 03/28/2001 | CN1288950A Preparation and application of monocloning antibody based on DNA immunity |
| 03/28/2001 | CN1063792C Hamanized antibodies and uses thereof |
| 03/28/2001 | CN1063756C Double antigen containing hepatitis B virus and hepatitis C virus core antigen simultaneously |
| 03/27/2001 | US6207805 Hybridoma which secretes monoclonal antibodies; diagnosis; anticarcinogenic agents with reduced side effects; imaging |
| 03/27/2001 | US6207803 Amino acid sequence of polypeptide; anticarcinogenic agents; antitumor agents; treatment of automimmune disorders, blood disorders; alzheimer's/parkinson's disease, septic shock, osteoporosis, polycystic kidney disease; viricides; diagnosis |
| 03/27/2001 | US6207801 FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same |
| 03/27/2001 | US6207703 Mucoadministering to airways formulation comprising antifungal agent to reduce or eliminate symptoms of asthma |
| 03/27/2001 | US6207647 Polynucleotides and polypeptides of the rat family, referred to as ?rata?; treatment of chlamydia infections |
| 03/27/2001 | US6207646 Immunostimulatory nucleic acid molecules |
| 03/27/2001 | US6207645 Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
| 03/27/2001 | US6207455 Lentiviral vectors |
| 03/27/2001 | US6207449 Nucleotide sequence of gene; hybridization probes for detection; drug screening for bactericides, bacteriostats and antibiotics |
| 03/27/2001 | US6207439 Prepared by microfiltration, ultrafiltration, and then gel filtration of infected cell culture; vaccines |
| 03/27/2001 | US6207416 Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines |
| 03/27/2001 | US6207413 Nucleotide sequence coding binding protein; for the diagnosis and treatment of endocrine defects |
| 03/27/2001 | US6207412 Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells |
| 03/27/2001 | US6207411 Bacteriocins |
| 03/27/2001 | US6207401 Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
| 03/27/2001 | US6207398 Lysing red blood cells in a sample of whole blood containing cyclosporin a, contacting the sample with excess of labeled anti-cyclosporin antibody to form a complex, separating unbound antibody, contacting complex with cyclosporins |
| 03/27/2001 | US6207386 Compositions for the treatment and diagnosis of body weight disorders, including obesity |
| 03/27/2001 | US6207374 Tuberous sclerosis 2 gene and uses thereof |
| 03/27/2001 | US6207185 Method for inducing a systemic immune response to an HIV antigen |
| 03/27/2001 | US6207171 Polyphosphazene microspheres |
| 03/27/2001 | US6207170 Extract from plasma membrane form malignant white blood cells |
| 03/27/2001 | US6207169 Compounds and methods for the diagnosis and treatment of Ehrlichia infection |
| 03/27/2001 | US6207168 Vaccine composition for herpes simplex virus and methods of using |
| 03/27/2001 | US6207167 Chicken leucocytozoon vaccine |
| 03/27/2001 | US6207166 Veterinary medicine |